The objective of this study is to assess the ability of intrathecal α-L-iduronidase to be administered safely 24 months [clinicaltrials_resource:3128850c9cb24b710ce9da544283406b]
The Experimental treatment group will receive study assessments and intrathecal laronidase (1.74 mg laronidase) treatments every 1-3 months beginning at start of study.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
The objective of this study is to assess the ability of intrathecal α-L-iduronidase to be administered safely 24 months [clinicaltrials_resource:3128850c9cb24b710ce9da544283406b]
The Experimental treatment group will receive study assessments and intrathecal laronidase (1.74 mg laronidase) treatments every 1-3 months beginning at start of study.
Bio2RDF identifier
3128850c9cb24b710ce9da544283406b
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:3128850c9cb24b710ce9da544283406b
measure [clinicaltrials_vocabulary:measure]
The objective of this study is ...... dase to be administered safely
time frame [clinicaltrials_vocabulary:time-frame]
description
The Experimental treatment gro ...... s beginning at start of study.
identifier
clinicaltrials_resource:3128850c9cb24b710ce9da544283406b
title
The objective of this study is ...... administered safely 24 months
@en
type
label
The objective of this study is ...... 8850c9cb24b710ce9da544283406b]
@en